| Literature DB >> 33852874 |
Harini Ramalingam1, Sonu Kashyap2, Patricia Cobo-Stark1, Andrea Flaten1, Chun-Mien Chang1, Sachin Hajarnis1, Kyaw Zaw Hein2, Jorgo Lika2, Gina M Warner2, Jair M Espindola-Netto2, Ashwani Kumar3, Mohammed Kanchwala3, Chao Xing4, Eduardo N Chini5, Vishal Patel6.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disorder marked by numerous progressively enlarging kidney cysts. Mettl3, a methyltransferase that catalyzes the abundant N6-methyladenosine (m6A) RNA modification, is implicated in development, but its role in most diseases is unknown. Here, we show that Mettl3 and m6A levels are increased in mouse and human ADPKD samples and that kidney-specific transgenic Mettl3 expression produces tubular cysts. Conversely, Mettl3 deletion in three orthologous ADPKD mouse models slows cyst growth. Interestingly, methionine and S-adenosylmethionine (SAM) levels are also elevated in ADPKD models. Moreover, methionine and SAM induce Mettl3 expression and aggravate ex vivo cyst growth, whereas dietary methionine restriction attenuates mouse ADPKD. Finally, Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced c-Myc and Avpr2 mRNA m6A modification and translation. Thus, Mettl3 promotes ADPKD and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.Entities:
Keywords: AVPR2; METTL3; N(6)-methyladenosine; S-adenosylmethionine; c-Myc; m6A mRNA methylation; mRNA translation; methionine; polycystic kidney disease
Mesh:
Substances:
Year: 2021 PMID: 33852874 PMCID: PMC8172529 DOI: 10.1016/j.cmet.2021.03.024
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 31.373